The Emirates Drug Establishment granted conditional approval for a new indication of AstraZeneca’s Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. This decision positions the UAE as the first country to authorise the treatment for that use. Ultomiris has been registered in the UAE since 2022 for several rare diseases, the establishment reported.
Primary immunoglobulin A nephropathy is the most common immune-mediated glomerular disease worldwide. A review published in JAMA Network estimated that the condition affects between 198,887 and 208,184 persons in the United States alone. Up to 50 percent of patients may develop kidney failure within 10 to 20 years of diagnosis, according to multiple clinical studies.
Elevated protein levels in urine represent a key marker of disease advancement, prompting updated clinical guidelines that target reduction below 0.5 grams per day. The conditional approval for Ultomiris addresses this need through complement inhibition to limit further kidney damage. Dr Ruqaya Aqeel Al Bastaki, acting executive director of the medical products regulation sector at the EDE, said the framework relies on rigorous scientific assessment while maintaining the highest standards of safety, quality and efficacy.
Sameh El Fangary, Gulf Cluster President at AstraZeneca, described the approval as an important step toward expanding treatment options for eligible patients. In comments carried by the EDE, he added that the company looks forward to continued collaboration with UAE partners to improve access, treatment outcomes and quality of care. The move supports the strategic priorities of the We the UAE 2031 vision in strengthening healthcare and pharmaceutical innovation.
The EDE’s action underscores its role in accelerating availability of emerging therapies based on scientific developments. Primary IgA nephropathy arises from immune protein deposits in kidney tissue that trigger inflammation and gradual functional decline, the establishment explained. Incidence of the condition peaks in younger adults and is highest in East Asia, a Merck Manual professional edition overview found.
Ultomiris is administered intravenously, with the new indication limited to those meeting progression risk criteria. The approval builds on the medicine’s prior use in other complement-mediated disorders. This development may influence regulatory reviews in other markets for similar kidney disease applications.
ع